Diabetic cardiomyopathy

Shishir Murarka, Mohammad R Movahed

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Individuals with diabetes are at a significantly greater risk of developing cardioymyopathy and heart failure despite adjusting for concomitant risks such as coronary artery disease or hypertension. This has led to the increased recognition of a distinct disease process termed as "diabetic cardiomyopathy." In this article, we perform an extensive review of the pathogenesis and treatment of this disease. From a clinical perspective, physicians should be aware of this entity, and early screening should be considered because physical evidence of early diabetic cardiomyopathy could be difficult to detect. Early detection of the disease should prompt intensification of glycemic control, concomitant risk factors, use of pharmacologic agents such as β-blockers and renin-angiotensin-aldosterone system antagosists. From a research perspective, more studies on myocardial tissue from diabetic patients are needed. Clinical trials to evaluate the development of diabetic cardiomyopathy and fibrosis in early stages of the disease, as well as clinical trials of pharmacologic intervention in patients specifically with diabetic cardiomyopathy, need to be conducted.

Original languageEnglish (US)
Pages (from-to)971-979
Number of pages9
JournalJournal of Cardiac Failure
Volume16
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Diabetic Cardiomyopathies
Clinical Trials
Renin-Angiotensin System
Coronary Artery Disease
Early Diagnosis
Fibrosis
Heart Failure
Hypertension
Physicians
Research

Keywords

  • Cardiomyopathy
  • Congestive heart failure
  • Diabetes
  • Diabetes and cardiomyopathy
  • DM
  • Heart failure
  • Systolic dysfunction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Diabetic cardiomyopathy. / Murarka, Shishir; Movahed, Mohammad R.

In: Journal of Cardiac Failure, Vol. 16, No. 12, 12.2010, p. 971-979.

Research output: Contribution to journalArticle

Murarka, Shishir ; Movahed, Mohammad R. / Diabetic cardiomyopathy. In: Journal of Cardiac Failure. 2010 ; Vol. 16, No. 12. pp. 971-979.
@article{6604adc237d7433788fb4dd8e0ca36e0,
title = "Diabetic cardiomyopathy",
abstract = "Individuals with diabetes are at a significantly greater risk of developing cardioymyopathy and heart failure despite adjusting for concomitant risks such as coronary artery disease or hypertension. This has led to the increased recognition of a distinct disease process termed as {"}diabetic cardiomyopathy.{"} In this article, we perform an extensive review of the pathogenesis and treatment of this disease. From a clinical perspective, physicians should be aware of this entity, and early screening should be considered because physical evidence of early diabetic cardiomyopathy could be difficult to detect. Early detection of the disease should prompt intensification of glycemic control, concomitant risk factors, use of pharmacologic agents such as β-blockers and renin-angiotensin-aldosterone system antagosists. From a research perspective, more studies on myocardial tissue from diabetic patients are needed. Clinical trials to evaluate the development of diabetic cardiomyopathy and fibrosis in early stages of the disease, as well as clinical trials of pharmacologic intervention in patients specifically with diabetic cardiomyopathy, need to be conducted.",
keywords = "Cardiomyopathy, Congestive heart failure, Diabetes, Diabetes and cardiomyopathy, DM, Heart failure, Systolic dysfunction",
author = "Shishir Murarka and Movahed, {Mohammad R}",
year = "2010",
month = "12",
doi = "10.1016/j.cardfail.2010.07.249",
language = "English (US)",
volume = "16",
pages = "971--979",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "12",

}

TY - JOUR

T1 - Diabetic cardiomyopathy

AU - Murarka, Shishir

AU - Movahed, Mohammad R

PY - 2010/12

Y1 - 2010/12

N2 - Individuals with diabetes are at a significantly greater risk of developing cardioymyopathy and heart failure despite adjusting for concomitant risks such as coronary artery disease or hypertension. This has led to the increased recognition of a distinct disease process termed as "diabetic cardiomyopathy." In this article, we perform an extensive review of the pathogenesis and treatment of this disease. From a clinical perspective, physicians should be aware of this entity, and early screening should be considered because physical evidence of early diabetic cardiomyopathy could be difficult to detect. Early detection of the disease should prompt intensification of glycemic control, concomitant risk factors, use of pharmacologic agents such as β-blockers and renin-angiotensin-aldosterone system antagosists. From a research perspective, more studies on myocardial tissue from diabetic patients are needed. Clinical trials to evaluate the development of diabetic cardiomyopathy and fibrosis in early stages of the disease, as well as clinical trials of pharmacologic intervention in patients specifically with diabetic cardiomyopathy, need to be conducted.

AB - Individuals with diabetes are at a significantly greater risk of developing cardioymyopathy and heart failure despite adjusting for concomitant risks such as coronary artery disease or hypertension. This has led to the increased recognition of a distinct disease process termed as "diabetic cardiomyopathy." In this article, we perform an extensive review of the pathogenesis and treatment of this disease. From a clinical perspective, physicians should be aware of this entity, and early screening should be considered because physical evidence of early diabetic cardiomyopathy could be difficult to detect. Early detection of the disease should prompt intensification of glycemic control, concomitant risk factors, use of pharmacologic agents such as β-blockers and renin-angiotensin-aldosterone system antagosists. From a research perspective, more studies on myocardial tissue from diabetic patients are needed. Clinical trials to evaluate the development of diabetic cardiomyopathy and fibrosis in early stages of the disease, as well as clinical trials of pharmacologic intervention in patients specifically with diabetic cardiomyopathy, need to be conducted.

KW - Cardiomyopathy

KW - Congestive heart failure

KW - Diabetes

KW - Diabetes and cardiomyopathy

KW - DM

KW - Heart failure

KW - Systolic dysfunction

UR - http://www.scopus.com/inward/record.url?scp=78649443999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649443999&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2010.07.249

DO - 10.1016/j.cardfail.2010.07.249

M3 - Article

C2 - 21111987

AN - SCOPUS:78649443999

VL - 16

SP - 971

EP - 979

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 12

ER -